DE60024649D1 - Verbindungen für die behandlung von ischämie - Google Patents

Verbindungen für die behandlung von ischämie

Info

Publication number
DE60024649D1
DE60024649D1 DE60024649T DE60024649T DE60024649D1 DE 60024649 D1 DE60024649 D1 DE 60024649D1 DE 60024649 T DE60024649 T DE 60024649T DE 60024649 T DE60024649 T DE 60024649T DE 60024649 D1 DE60024649 D1 DE 60024649D1
Authority
DE
Germany
Prior art keywords
ischemia
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024649T
Other languages
English (en)
Inventor
Hiroko Masamune
Paul Deninno
William Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60024649D1 publication Critical patent/DE60024649D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60024649T 1999-09-30 2000-09-22 Verbindungen für die behandlung von ischämie Expired - Lifetime DE60024649D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30
PCT/IB2000/001353 WO2001023399A1 (en) 1999-09-30 2000-09-22 Compounds for the treatment of ischemia

Publications (1)

Publication Number Publication Date
DE60024649D1 true DE60024649D1 (de) 2006-01-12

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024649T Expired - Lifetime DE60024649D1 (de) 1999-09-30 2000-09-22 Verbindungen für die behandlung von ischämie

Country Status (41)

Country Link
EP (1) EP1216257B1 (de)
JP (1) JP2003510331A (de)
KR (1) KR100481605B1 (de)
CN (1) CN1374967A (de)
AP (1) AP2002002458A0 (de)
AR (1) AR029887A1 (de)
AT (1) ATE312117T1 (de)
AU (1) AU778185B2 (de)
BG (1) BG106636A (de)
BR (1) BR0014384A (de)
CA (1) CA2386079A1 (de)
CO (1) CO5180581A1 (de)
CR (1) CR6592A (de)
CZ (1) CZ20021020A3 (de)
DE (1) DE60024649D1 (de)
EA (1) EA005422B1 (de)
EC (1) ECSP003682A (de)
EE (1) EE200200172A (de)
GE (1) GEP20043241B (de)
GT (1) GT200000161A (de)
HK (1) HK1049011A1 (de)
HR (1) HRP20020253A2 (de)
HU (1) HUP0202807A3 (de)
IL (1) IL148222A0 (de)
IS (1) IS6286A (de)
MA (1) MA26822A1 (de)
MX (1) MXPA02003308A (de)
MY (1) MY133996A (de)
NO (1) NO20021474L (de)
NZ (1) NZ517177A (de)
OA (1) OA12021A (de)
PA (1) PA8503301A1 (de)
PE (1) PE20010696A1 (de)
PL (1) PL357371A1 (de)
SK (1) SK4182002A3 (de)
TN (1) TNSN00191A1 (de)
TR (1) TR200200843T2 (de)
UA (1) UA73525C2 (de)
WO (1) WO2001023399A1 (de)
YU (1) YU23102A (de)
ZA (1) ZA200202461B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (de) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purinderivate zur Behandlung von Ischämie
JP2005511590A (ja) * 2001-11-02 2005-04-28 アベンティス・ファーマスーティカルズ・インコーポレイテツド アデノシンa1/a2アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP1494685B1 (de) * 2002-04-18 2008-12-31 Cv Therapeutics, Inc. Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
JP2007513082A (ja) * 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ccr−5アンタゴニストとして有用なベンジルエーテルアミン化合物
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CN101132802A (zh) 2004-03-24 2008-02-27 法斯根有限责任公司 通过药理学抑制amp-活化的蛋白激酶的神经保护的新方法
US9012494B2 (en) 2004-05-07 2015-04-21 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DK1778239T3 (da) * 2004-07-28 2013-12-02 Can Fite Biopharma Ltd Adenosin-a3-receptor-agonister til behandling af sygdomme forbundet medtørre øjne, herunder sjögrens syndrom
CA2576255A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
MY141198A (en) 2004-08-30 2010-03-31 Janssen Pharmaceutica Nv Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
KR101197674B1 (ko) 2004-08-30 2012-11-07 얀센 파마슈티카 엔.브이. 11-베타 하이드록시스테로이드 탈수소효소 저해제로서의 n-2 아다만타닐-2-페녹시-아세트아미드 유도체
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
IN2012DN01453A (de) 2009-08-20 2015-06-05 Novartis Ag
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3964513A1 (de) 2012-04-03 2022-03-09 Novartis AG Kombinationsprodukte mit tyrosinkinaseinhibitoren und deren verwendung
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US9949991B2 (en) * 2013-11-06 2018-04-24 Aeromics, Inc. Methods of treating aquaporin-mediated conditions
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (de) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
AU7331094A (en) * 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists

Also Published As

Publication number Publication date
CA2386079A1 (en) 2001-04-05
UA73525C2 (en) 2005-08-15
BR0014384A (pt) 2002-07-02
OA12021A (en) 2006-04-19
PA8503301A1 (es) 2003-06-30
EA200200316A1 (ru) 2002-08-29
PE20010696A1 (es) 2001-07-05
EP1216257A1 (de) 2002-06-26
PL357371A1 (en) 2004-07-26
TR200200843T2 (tr) 2002-07-22
CO5180581A1 (es) 2002-07-30
EP1216257B1 (de) 2005-12-07
HK1049011A1 (zh) 2003-04-25
EE200200172A (et) 2003-06-16
AP2002002458A0 (en) 2002-06-30
SK4182002A3 (en) 2003-04-01
BG106636A (bg) 2003-01-31
HRP20020253A2 (en) 2004-04-30
CN1374967A (zh) 2002-10-16
AU778185B2 (en) 2004-11-18
AU7035200A (en) 2001-04-30
NZ517177A (en) 2003-10-31
YU23102A (sh) 2006-01-16
GT200000161A (es) 2002-03-22
NO20021474D0 (no) 2002-03-25
HUP0202807A2 (hu) 2002-12-28
CR6592A (es) 2004-02-23
IS6286A (is) 2002-02-26
HUP0202807A3 (en) 2005-02-28
ATE312117T1 (de) 2005-12-15
CZ20021020A3 (cs) 2003-04-16
AR029887A1 (es) 2003-07-23
TNSN00191A1 (fr) 2005-11-10
ECSP003682A (es) 2002-04-23
MY133996A (en) 2007-11-30
GEP20043241B (en) 2004-05-25
MXPA02003308A (es) 2002-10-04
JP2003510331A (ja) 2003-03-18
EA005422B1 (ru) 2005-02-24
IL148222A0 (en) 2002-09-12
ZA200202461B (en) 2003-05-28
KR100481605B1 (ko) 2005-04-08
WO2001023399A1 (en) 2001-04-05
MA26822A1 (fr) 2004-12-20
NO20021474L (no) 2002-05-22
KR20020034206A (ko) 2002-05-08

Similar Documents

Publication Publication Date Title
DE60024649D1 (de) Verbindungen für die behandlung von ischämie
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
DE69928792D1 (de) Imidazo-pyridin verbindungen, die die sekretion von magensäure hemmen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE60316538D1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60016794D1 (de) Intraspinale botulinus-toxin-enthaltende verbindungen zur schmerzbehandlung
DE60001421D1 (de) Behandlung von abgas
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
EE04747B1 (et) Amiini-plaatina komplekside valmistamismeetod
DE60043868D1 (de) Abgeschwächte Mikroorganismen für die Behandlung von Infektionen
ATE276262T1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE69905214D1 (de) Mittel zur Behandlung der Osteoporose
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
ATE253556T1 (de) Aminoacylaroylpyrrole für die behandlung des neuropathischen schmerzes

Legal Events

Date Code Title Description
8332 No legal effect for de